

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Ublituximab for treating relapsing multiple sclerosis

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Multiple sclerosis is two-to-three times as common in females than males. A stakeholder commented that pregnancy can restrict access to disease modifying therapy which can impact treatment choices for this patient group.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee should consider whether a draft recommendation would make it harder for any gender to access ublituximab.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No, the higher prevalence in females is already noted in the draft scope.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
No

Approved by Associate Director (name): Emily Crowe

Date: 03/06/2024